ABSTRACT
INTRODUCTION
Cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic persistent liver injury, which leads to portal hypertension, ascites and end-stage liver disease. Liver fibrosis is a dynamic process which results from the perpetuation of the normal wound healing response resulting in an abnormal continuation of fibrogenesis [connective tissue production and deposition]. [1] [2] [3] [4] [5] Progresses of fibrosis occurs at variable rates, depending on the cause of liver disease, environmental and host factors. 1 The major clinical consequences of cirrhosis are Alcoholic liver disease and hepatitis C are the most common etiologies of liver fibrosis in the Western world, while hepatitis B prevails in most parts of Asia and sub-Saharan Africa. 1 Alcohol consumption is estimated to cause from 20% to 50% of cirrhosis of the liver. 3 After the identification of the hepatitis C virus in 1989 and of non-alcoholic steatohepatitis [NASH] in obese and diabetic subjects, the diagnosis of cirrhosis without an apparent cause [ Liver cirrhosis is a significant cause of global health burden, with more than one million deaths in 2010. Mortality from liver cirrhosis was also comparatively high in countries of Central Asia, particularly Mongolia, Uzbekistan and Kyrgyzstan, and in parts of sub-Saharan Africa. 4 The physicians of Unani system of Medicine have been treating cirrhosis of liver and its consequences since centuries. The entity "Warm-e-Jigar Barid Saudawi"/ "Taleef-ul-Kabid" in Unani literature, mimic liver cirrhosis and associated constellation of symptoms. A large number of single and compound drug preparation have been documented in the treatment of Taleef-ul-Kabid. These scientific studies have validated the antioxidant, anti-inflammatory, antiviral, immuno-modulatory, and hepatoprotective nature of plant-based medicines, and their bioactive principle has been isolated and characterized.
The cases who were treated in the present series includes only those who were advised for liver transplantation. Due to nonavailability of donor and certain factors such as restricted and costlier resources in overpopulated India, Unani treatment has been given in these cases as per Unani paradigms documented in Unani literature for cirrhosis of liver. Unani treatment, given in this case series comprised of multiple poly-herbal or compound preparation of Unani medicine.
OBJECTIVE
Present case series was performed, primarily aimed to explore the antifibrotic and liver regenerating effect of Unani treatment in the three cases of liver cirrhosis.
CASE PRESENTATION

Consent
Informed consent was taken from the patients. The human data's, included in this case series were obtained in compliance with the Declaration of Helsinki. Table 1 provides a summary of the relevant biomarkers in these three cases. Table 2 is summary of quality of life assessment in these 3 cases. The immune system [both the innate and the adaptive immune cells] plays an important role in fibrosis, since persistent inflammation almost always accompanies fibrosis. In our cases, reduction in fibrosis could be due to immunomodulatory effect of the constituents in above mentioned Unani treatment, proven in various animal models. 11, 21, 22 Since chronic inflammation almost always precedes and accompanies fibrotic changes and the medicines that target the inflammatory cascade typically have antifibrotic activity. Moreover, because the vicious cycle of scar formation is initiated by oxidative stress, targeting ROS generation also reduces the inflammatory response, which will attenuate HSC activation and fibrogenesis. Antioxidants can attenuate ROS effects and hold promise as potential antifibrotic therapies,
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provided that sufficient antioxidant activity can be delivered to the sites of injury within the liver.
Antioxidants exert a preventive effect on hepatocyte injury but may also be directly antifibrogenic. 6 
23,24
Jigreen, has been proven for its effects on anorexia, pain in abdomen, nausea and vomiting, probably the cause for symptomatic relief in our cases. Jigreen has also reduced bilirubin levels and improved other liver biochemical markers. 8 
CONCLUSION
This case report provides a novel direction in which above mentioned Unani treatment can be used for regeneration of liver and halting progression of fibrosis in cirrhosis and for alleviation of constellation of symptoms. Unani treatment also improved quality of life in these three cases. Therefore further studies should be performed to warrant the antifibrotic and regenerative effect along with elucidation of mechanism of action of Unani treatment in cirrhosis of liver.
